title: Effects of cetirizine and epinastine on the skin response to histamine iontophoresis.
abstract: Epinastine and cetirizine are second-generation, nonsedating and long-lasting antihistamines that are now frequently used for the allergic disorders. We have examined the inhibitory effects of these two drugs on the histamine-induced flare and wheal responses using iontophoresis at 1, 2, 4, 8 and 24 h after the oral administration by a double-blind, cross-over and placebo-controlled study. Both cetirizine and epinastine significantly inhibited the histamine-induced flare and wheal responses at 2 h after the oral administration when compared with placebo. The inhibitory effects of cetirizine and epinastine on the flare response lasted long until at 24 h, however, epinastine was less potent than cetirizine. The inhibitory effects on the wheal response was also clearly and significantly evident at 2-8 h by cetirizine and epinastine. At 24 h cetirizine only showed the significant inhibition on the histamine-induced wheal response. In contrast, epinastine seemed to exhibit the inhibitory capacity earlier than did cetirizine. The inhibitory action of the drugs on the histamine-induced wheal response peaked at 4 h after the oral administration. The histamine-induced itch sensation was also markedly or completely suppressed at 2-8 h by the drugs. Thus, both drugs exhibited the potent and long-lasting antihistamine activity on the skin responses induced by histamine iontophoresis.
authors.affiliation: Department of Dermatology, Graduate School of Medical Sciences, 3-1-1 Maidashi, Higashiku, 812, Fukuoka, Japan. furue@dermatol.med.kyushu-u.ac.jp
authors.forename: M
authors.initials: M
authors.lastname: Furue
authors.forename: H
authors.initials: H
authors.lastname: Terao
authors.forename: T
authors.initials: T
authors.lastname: Koga
mesh_terms: D000284:Administration, Oral; D000328:Adult; D017332:Cetirizine / Q000627:therapeutic use*; D018592:Cross-Over Studies; D003876:Dermatitis, Atopic / Q000188:drug therapy* / Q000473:pathology; D003984:Dibenzazepines / Q000627:therapeutic use*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006632:Histamine / Q000008:administration & dosage*; D006634:Histamine H1 Antagonists / Q000627:therapeutic use*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D007478:Iontophoresis; D008297:Male; D012867:Skin / Q000187:drug effects*
chemical_list: D003984:Dibenzazepines; D006634:Histamine H1 Antagonists; D007093:Imidazoles; D006632:Histamine; C053090:epinastine; D017332:Cetirizine